AbbVie (NYSE:ABBV) said that it presented new results from a Phase 2 study of investigational compound venetoclax (ABT-199/GDC-0199) in patients with acute myelogenous leukemia or AML at the 56th American Society of Hematology Annual Meeting. AbbVie Inc. (NYSE:ABBV) belongs to Healthcare sector. Its net profit margin is 18.90% and weekly performance is 0.74%. On last trading day company shares ended up $69.71. AbbVie Inc. (NYSE:ABBV) … Continue reading Stocks Swings: AbbVie Inc. (NYSE:ABBV), Yelp, Inc. (NYSE:YELP), Universal Health Services Inc. (NYSE:UHS), Tompkins Financial Corporation (NYSEMKT:TMP), Walgreen Co. (NYSE:WAG)